In August 2015, Sorrento entered into an exclusive licensing agreement to develop and commercialize four, late-stage clinical biosimilar or biobetter antibodies based on Erbitux®, Remicade®, Xolair®, and Simulect® for the North American, European and Japanese markets from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China. Each of these four antibody programs has already completed Phase 3 clinical studies in China.
“We look at our Mabtech collaboration as a transformational event for Sorrento and are excited about its potential to complement our expanding and deep biologics portfolio”
– CEO Henry Ji
These biosimilar antibodies are:
- cetuximab targeting the epithelial growth factor receptor (EGFR)
- infliximab targeting tumor necrosis factor alpha (TNF-α)
- omalizumab targeting IgE
- basiliximab targeting the alpha chain of the interleukin-2 receptor (IL-2Rα or CD25).
Each of the four antibodies has completed a Phase III study in China.
The combination of Sorrento’s expertise in immunotherapy and drug development with Mabtech’s experience in antibody development and commercial cGMP manufacturing positions Sorrento Therapeutics as a major player in the biopharmaceutical industry to increase access to effective biosimilars.